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Accordingly, publication of the paper by Koshiko and
colleagues is timely because it specifically addresses the
question of whether ISRG is effective in the presence of
more virulent organisms, such as MRSA and Escherichia
coli. Their data suggest that the gelatin sealant and antibac-
terial activity remained for about 2 weeks after implanta-
tion (actually more than was previously expected8). In vitro
study results suggested that ISRGs were effective against
S epidermidis infections for 2 to 3 weeks but retained suf-
ficient antibacterial activity for only 48 hours against
MRSA and E coli. Finally, in vivo animal study results
appeared to corroborate the in vitro findings regarding the
inability of ISRGs to protect against ongoing perigraft
infection in the presence of MRSA and E coli. Their con-
clusion was that ISRG was a potential option for the treat-
ment of S epidermidis infections but that it was “inapplicable”
to use them in the presence of more virulent organisms.
At first sight, these seem to be rather damning data for
the proponents of ISRG, particularly because autologous
venous conduits (superficial femoral, greater saphenous)
have emerged as alternative options for in situ revasculariza-
tion.9 However, even assuming that their conclusions
regarding MRSA are correct (which I think they are), before
abandoning the potential benefits of ISRG in other types of
graft infection (shorter procedure in ill patients, no lower
limb venous complications), a number of issues regarding
the design of Koshiko et al’s study must be considered.
First, the authors prepared their rifampicin solution 24
hours before graft irrigation. In normal clinical practice,
the solution is prepared in theatre and immediately applied
to the graft. The authors conceded that the antibacterial
activity decreased with time at room temperature, but it
would be interesting to know whether validation studies
had been done on their 24-hour refrigerated samples.
Second, a low concentration of rifampicin was used in this
study (1 mg/mL). In almost every clinical series published
to date, the concentration of rifampicin has been 60
mg/mL (600 mg rifampicin in 10 mL solvent), and this
may be clinically important. Third, although it is accepted
that the standard National Committee for Clinical
Laboratory Standards method for gauging antibiotic activ-
ity requires the inoculation of 2 mL solution containing 1
to 2  108 organisms directly onto the graft, it remains to
be seen whether this truly reflects the natural history of
the evolution of graft infection in clinical practice as
opposed to the innoculum required to secure a graft infec-
tion. Intuitively, one believes that a spectrum of contami-
nation is inevitably encountered in normal graft infection
patients. Accordingly, the large bacterial load may reflect
The rationale underlying planning treatment of major
aortic graft infection (MAGI) is, at first sight, deceptively
simple: eradication of infection, minimization of the oper-
ative risk, and prevention of recurrence. In the early
1990s, total graft excision (TGE) with in situ replacement
with a rifampicin-bonded graft (ISRG) was introduced as
a potential alternative to the “gold standard” of TGE with
extraanatomic bypass.1-5 ISRG offered the prospect of a
shorter operation time, less physiologic stress to an already
sick patient, and optimal pelvic and lower limb blood flow,
and it avoided the risk of aortic stump blow-out and late
amputation after thrombosis of axillofemoral grafts.2-5
The principal worry, however, was whether short-term
gain (reduced operative mortality and amputation rates)
was to be exchanged for long-term pain (reinfection and
its sequelae).
In fact, a review of the four largest series published to
date suggests that the results of ISRG appear to be
extremely good.2-5 The operative mortality rate was 5%, the
early and late amputation rate was 0%, and the reinfection
rate was a gratifying 15%. However, these results may not
be generalizable to routine clinical practice. First, only 40
patients were reported in these studies. Second, the largest
experience by Bandyk et al5 (16 patients) was highly
selected and largely comprised patients with Staphylococcus
epidermidis MAGI. It was also unclear as to the actual rate
of reinfection in this series.5 Third, many of the patients
underwent treatment in the era before the widespread
emergence of methicillin-resistant Staphylococcus aureus
(MRSA). In the updated Leicester series,3 we observed that
ISRG was probably unwise in patients with MRSA.
Subsequently, a 1-year prospective audit by the Joint
Vascular Research Group (JVRG), a collaboration of acade-
mic vascular research units, found that MRSA was now the
predominant organism responsible for complex wound and
graft infections in the United Kingdom and Ireland.
Moreover, MRSA infections were associated with an
extremely poor outcome, irrespective of location.6 Even
native artery and autologous vein was not immune.6,7
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an unlikely clinical scenario (with respect to direct conta-
mination), and it cannot represent the typical volume of
contamination in hematologically mediated graft infec-
tion. Fourth (and very importantly), none of the animals
received any antibiotics, either prophylactically or thera-
peutically. It would certainly be our practice to treat sus-
pected MAGI with systemic, broad-spectrum antibiotics
until cultures and sensitivities were available, revise them
thereafter, and continue treatment for at least 6 weeks.
Finally, most exponents of TGE and ISRG would nor-
mally wrap the bonded graft with omentum to protect the
prosthesis from potentially infected perigraft tissues. This
was not done in any of the animals. In this respect, it is
interesting to observe that no positive MRSA or E coli cul-
ture results were obtained directly from the ISRG grafts at
death, whereas the perigraft tissues always had positive
results. It is possible that omental wrapping may have
given the host’s immune response a chance to counter the
perigraft infection, especially if antibiotics had also been
administered.
In summary, this paper has rightly focused attention
on the role of ISRG in MAGI. I think that almost every
vascular surgeon would now be reluctant to consider
ISRG as a first line option in patients with suspected
MRSA aortic infection. However, the available clinical evi-
dence2-5 suggests that ISRG may still have an important
role in the management of other types of infection, includ-
ing some of the more virulent subtypes. This must be clar-
ified before a potentially important treatment option is
discarded. However, as was alluded to earlier, only 40
cases formed the basis of the clinical review for this com-
mentary. Many more patients, worldwide, must have
undergone treatment with ISRG, and it would be helpful
to know of early and late outcomes with respect to the
type of organism cultured at operation and the type of pre-
sentation (low-grade infection, enteric fistula, abscess,
gross sepsis).
The one problem facing all of us is that we usually do
not know what the responsible organism is until after the
operation, despite preoperative and perioperative cultures
and gram stains. It may be that only the “good results” after
ISRG have been published to date. Those investigators with
poorer outcomes should be encouraged to submit their
data so as to make the evidence more generalizable. In an
ideal world, the issue would be settled with a randomized
trial. Members of the JVRG have considered this, but there
were many logistic difficulties, not least the numbers
needed for valid statistical analysis and the inevitable prob-
lems with inclusion and exclusion criteria. For many, the
emergence of MRSA has already changed everything. The
evidence from the JVRG audit was that once MRSA was
identified as being responsible for the graft infection, treat-
ment tended to be graft excision and amputation with the
primary aim being preservation of life.6 In situ reconstruc-
tion with autologous tissues may seem to be an attractive
option, but the JVRG experience is that neither they nor
native artery are a barrier to MRSA infection.6,7 It remains
to be seen whether the respective roles for ISRG, in situ
revascularization with autologous vein, or TGE with
extraanatomic bypass can be clarified before fear of MRSA
dictates all management decisions.
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